Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

This week in Drug Discovery (20-24 July 2026) 

Published

on

""

News round-up for 20-24 July by Megan Thomas, Content Team at DDW. 

This week’s news roundup highlights the latest advances in cancer research and treatment, from promising clinical trial updates to discoveries that could improve the body’s immune response to tumours. The top stories include progress in therapies for breast cancer, renal cell carcinoma, sarcoma and rare cancers, alongside new research that sheds light on how the immune system organises its attack against cancer.

The top stories: 

Phase II triple-negative breast cancer trial restarts

Intensity Therapeutics has administered INT230-6 in the INVINCIBLE-4 Study in Switzerland. The clinical biotechnology company is focused on the discovery and development of novel intratumoural cancer therapies that are designed to kill tumours and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology.

Read more…

Allogeneic CAR-T achieves durable remissions in metastatic solid tumours

Allogene Therapeutics has announced the publication of complete Phase I data from the TRAVERSE study of ALLO-316 in advanced or metastatic renal cell carcinoma (RCC) in the Journal of Clinical Oncology.

Read more… 

Phase I/II trial will assess sarcoma metastatic recurrence prevention

Mirador Therapeutics has entered into an exclusive worldwide license agreement with Kira Pharmaceuticals for KP-301, a potentially long-acting, sweeping anti-C5a antibody designed to inhibit C5a/C5aR-mediated inflammation.

Read more… 

Cancer Research UK leads global trial of rare cancer therapy

Biotechnology company Cytovation and the Norwegian Cancer Society (NCS) have joined forces with Cancer Research UK for the trial of people with advanced adrenocortical carcinoma (ACC), a rare and aggressive cancer.

Read more… 

Dendritic cells found to organise cancer-fighting immune hubs

KQ Labs, led by the Francis Crick Institute and Medicines Discovery Catapult (MDC), is an annual five-month programme for early-stage companies building science-backed, scalable solutions in AI-driven drug discovery, digital health, and precision medicine.

Read more… 

The post This week in Drug Discovery (20-24 July 2026)  appeared first on Drug Discovery World (DDW).

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

New webinar: Tackling drug discovery challenges in cancer research

Published

on

Cancer cells

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.

You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.

Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.

Q&A with the speakers follows the presentations.

Register for free now.

The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).

Continue Reading

Uncategorized

Psilocybin proves promising in neuropathic pain mouse study

Published

on

Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.

Continue Reading

Uncategorized

New Spectrometry Technique Could Aid Formulation Development

New Spectrometry Technique Could Aid Formulation Development

Published

on

A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.

According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.

“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”

Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.

The challenge is understanding the link between these things within a heterogeneous sample, he says.

To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.

He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.

Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.

Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.

The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Trending

Helixgate Biotech Review July Issue QR CodeScan to Read